{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T21:07:24Z","timestamp":1771362444703,"version":"3.50.1"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1097\/hjh.0b013e3283638194","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T22:51:34Z","timestamp":1380322294000},"page":"2109-2117","source":"Crossref","is-referenced-by-count":20,"title":["The unappreciated importance of blood pressure in recent and older atrial fibrillation trials"],"prefix":"10.1097","volume":"31","author":[{"given":"Athanasios","family":"Manolis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Doumas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonidas","family":"Poulimenos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manolis","family":"Kallistratos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210208","doi-asserted-by":"crossref","first-page":"2N","DOI":"10.1016\/S0002-9149(98)00583-9","article-title":"Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.","volume":"82","author":"Kannel","year":"1998","journal-title":"Am J Cardiol"},{"key":"R2-2-20210208","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/HJH.0b013e32834f03bf","article-title":"Hypertension and atrial fibrillation: diagnostic approach, prevention, and treatment. Position paper of the working group Hypertension, Arrhythmias and Thrombosis of the European Society of Hypertension.","volume":"30","author":"Manolis","year":"2012","journal-title":"J Hypertens"},{"key":"R3-2-20210208","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004872-200401000-00003","article-title":"Worldwide prevalence of hypertension: a systematic review.","volume":"22","author":"Kearney","year":"2004","journal-title":"J Hypertens"},{"key":"R4-2-20210208","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"R5-2-20210208","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","article-title":"Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document.","volume":"27","author":"Mancia","year":"2009","journal-title":"J Hypertens"},{"key":"R6-2-20210208","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Prospective Studies CollaborationAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"R7-2-20210208","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1212\/WNL.43.1_Part_1.32","article-title":"on behalf of the SPAF InvestigatorsIschemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism.","volume":"43","author":"Miller","year":"1993","journal-title":"Neurology"},{"key":"R8-2-20210208","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1052-3057(10)80166-1","article-title":"Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study.","volume":"5","year":"1995","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R9-2-20210208","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1161\/01.STR.30.6.1223","article-title":"on behalf of the SPAF InvestigatorsFactors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III Clinical Trials.","volume":"30","author":"Hart","year":"1999","journal-title":"Stroke"},{"key":"R10-2-20210208","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jama.290.8.1049","article-title":"A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study.","volume":"290","author":"Wang","year":"2003","journal-title":"JAMA"},{"key":"R11-2-20210208","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1136\/bmj.1.5392.1209","article-title":"Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease.","volume":"5392","author":"Szekely","year":"1964","journal-title":"BMJ"},{"key":"R12-2-20210208","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0140-6736(07)61300-2","article-title":"Management of atrial fibrillation.","volume":"370","author":"Lip","year":"2012","journal-title":"Lancet"},{"key":"R13-2-20210208","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"R14-2-20210208","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","article-title":"Analysis of pooled data from five randomized controlled trials.","volume":"154","year":"1994","journal-title":"Arch Intern Med"},{"issue":"suppl","key":"R15-2-20210208","doi-asserted-by":"crossref","first-page":"204S","DOI":"10.1378\/chest.126.3_suppl.204S","article-title":"The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.","volume":"126","author":"Ansell","year":"2004","journal-title":"Chest"},{"key":"R16-2-20210208","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/01.STR.0000208294.46968.a4","article-title":"Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation.","volume":"37","author":"Birman-Deych","year":"2006","journal-title":"Stroke"},{"key":"R17-2-20210208","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Blood Pressure Lowering Treatment Trialists CollaborationEffects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials.","volume":"362","author":"Turnbull","year":"2003","journal-title":"Lancet"},{"key":"R18-2-20210208","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/HJH.0b013e3283469976","article-title":"Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73913 patients.","volume":"29","author":"Reboldi","year":"2011","journal-title":"J Hypertens"},{"key":"R19-2-20210208","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/oxfordjournals.bmb.a072892","article-title":"Blood pressure, antihypertensive drug treatment and the risk of stroke and of coronary heart disease.","volume":"50","author":"Collins","year":"1994","journal-title":"Br Med Bull"},{"key":"R20-2-20210208","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/01.hjh.0000226212.34055.86","article-title":"Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial.","volume":"24","author":"Arima","year":"2006","journal-title":"J Hypertens"},{"key":"R21-2-20210208","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"6105 individuals with previous stroke or transient ischaemic attack.","volume":"358","year":"2001","journal-title":"Lancet"},{"key":"R22-2-20210208","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC guidelines for the management of atrial fibrillation.","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"R23-2-20210208","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1161\/CIR.0b013e3181fa3cf4","article-title":"3rd, et al. 2011 Writing Group Members, 2006 Writing Committee Members, ACCFAHA Task Force Members. 2011 ACCFAHAHRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology FoundationAmerican Heart Association Task Force on Practice Guidelines.","volume":"123","author":"Wann","year":"2011","journal-title":"Circulation"},{"key":"R24-2-20210208","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1161\/CIR.0b013e31820f14c0","article-title":"American College of Cardiology FoundationAmerican Heart Association Task Force. 2011 ACCFAHAHRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology FoundationAmerican Heart Association Task Force on Practice Guidelines.","volume":"123","author":"Wann","year":"2011","journal-title":"Circulation"},{"key":"R25-2-20210208","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"R26-2-20210208","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cjca.2012.01.021","article-title":"Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 Update of the Canadian Cardiovascular Society Atrial fibrillation Guidelines: recommendations for stroke prevention and raterhythm control.","volume":"28","author":"Skanes","year":"2012","journal-title":"Can J Cardiol"},{"key":"R27-2-20210208","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"R28-2-20210208","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"R29-2-20210208","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation.","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"R30-2-20210208","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation.","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"R31-2-20210208","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Executive Steering Committee for the SPORTIF III InvestigatorsStroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation.","volume":"362","author":"Olsson","year":"2003","journal-title":"Lancet"},{"key":"R32-2-20210208","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.","volume":"293","author":"Albers","year":"2005","journal-title":"JAMA"},{"key":"R33-2-20210208","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1474-4422(12)70017-0","article-title":"Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischemic attack: a predefined subgroup analysis from AVERROES, a randomized trial.","volume":"11","author":"Diener","year":"2012","journal-title":"Lancet Neurol"},{"key":"R34-2-20210208","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(96)03487-3","article-title":"Adjusted dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial.","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"R35-2-20210208","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0735-1097(91)90585-W","article-title":"for the CAFA studyCanadian Atrial Fibrillation Anticoagulation (CAFA) study.","volume":"18","author":"Connolly","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"R36-2-20210208","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"for the Veteran Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation InvestigatorsWarfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation.","volume":"327","author":"Ezekowitz","year":"1992","journal-title":"N Engl J Med"},{"key":"R37-2-20210208","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archinte.158.14.1513","article-title":"Fixed minidose warfarin and aspirin alone and in combination versus adjusted-dose warfarin for stroke prevention in atrial fibrillation.","volume":"158","author":"Gullov","year":"1998","journal-title":"Arch Intern Med"},{"key":"R38-2-20210208","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/bmj.319.7215.958","article-title":"Primary prevention of arterial thromboembolism in nonrheumatic atrial fibrillation in primary care: randomized controlled trial comparing two intensities of coumarin and aspirin.","volume":"319","author":"Hellemons","year":"1999","journal-title":"BMJ"},{"key":"R39-2-20210208","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0002-9149(98)00357-9","article-title":"Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation.","volume":"82","author":"Pengo","year":"1998","journal-title":"Am J Cardiol"},{"key":"R40-2-20210208","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.STR.31.4.817","article-title":"Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation.","volume":"31","author":"Yamaguchi","year":"2000","journal-title":"Stroke"},{"key":"R41-2-20210208","first-page":"527","article-title":"Final results.","volume":"84","year":"1991","journal-title":"Circulation"},{"key":"R42-2-20210208","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized, controlled trial.","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"R43-2-20210208","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa021328","article-title":"Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation.","volume":"347","author":"Wyse","year":"2002","journal-title":"N Engl J Med"},{"key":"R44-2-20210208","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa021375","article-title":"A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.","volume":"347","author":"van Gelder","year":"2002","journal-title":"N Engl J Med"},{"key":"R45-2-20210208","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMoa0803778","article-title":"ATHENA InvestigatorsEffect of dronedarone on cardiovascular events in atrial fibrillation.","volume":"360","author":"Hohnloser","year":"2009","journal-title":"N Engl J Med"},{"key":"R46-2-20210208","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(00)03230-X","article-title":"Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF) - a randomised trial.","volume":"356","author":"Hohnloser","year":"2000","journal-title":"Lancet"},{"key":"R47-2-20210208","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/S0735-1097(03)00332-2","article-title":"Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study.","volume":"41","author":"Carlsson","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R48-2-20210208","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1378\/chest.126.2.476","article-title":"Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study.","volume":"126","author":"Opolski","year":"2004","journal-title":"Chest"},{"key":"R49-2-20210208","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)90944-Z","article-title":"Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reduction in blood pressure: overview of randomized drug trials in their epidemiological context.","volume":"335","author":"Collins","year":"1990","journal-title":"Lancet"},{"key":"R50-2-20210208","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"for the ACCORD study groupEffects of intensive blood pressure control in type 2 diabetes mellitus.","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"R51-2-20210208","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1161\/CIRCULATIONAHA.110.008870","article-title":"Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET).","volume":"124","author":"Mancia","year":"2011","journal-title":"Circulation"},{"key":"R52-2-20210208","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jacc.2011.09.040","article-title":"Safety and efficacy of low blood pressures among patients with diabetes.","volume":"59","author":"Redon","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R53-2-20210208","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/01.HYP.0000259104.60878.43","article-title":"Differences in blood pressure control and stroke mortality across Spain.","volume":"49","author":"Redon","year":"2007","journal-title":"Hypertension"},{"key":"R54-2-20210208","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1161\/01.HYP.0000259106.77783.f8","article-title":"Using public health indicators to measure the success of hypertension control.","volume":"49","author":"Cooper","year":"2007","journal-title":"Hypertension"},{"key":"R55-2-20210208","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1161\/01.STR.0000181115.59173.42","article-title":"Perindopril-based blood pressure lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack.","volume":"36","author":"Arima","year":"2005","journal-title":"Stroke"},{"key":"R56-2-20210208","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1161\/STROKEAHA.108.514935","article-title":"Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation.","volume":"39","author":"Hylek","year":"2008","journal-title":"Stroke"},{"key":"R57-2-20210208","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/eurheartj\/ehl504","article-title":"Effect of hypertension on anticoagulated patients with atrial fibrillation.","volume":"28","author":"Lip","year":"2007","journal-title":"Eur Heart J"},{"key":"R58-2-20210208","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/STROKEAHA.112.650614","article-title":"Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran. The RE-LY trial.","volume":"43","author":"Hart","year":"2012","journal-title":"Stroke"},{"key":"R59-2-20210208","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1161\/01.STR.0000170642.39876.f2","article-title":"Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas.","volume":"36","author":"Hart","year":"2005","journal-title":"Stroke"},{"key":"R60-2-20210208","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00003495-200969060-00001","article-title":"Pharmacotherapy for the secondary prevention of stroke.","volume":"69","author":"Toyoda","year":"2009","journal-title":"Drugs"},{"key":"R61-2-20210208","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1161\/STROKEAHA.112.651448","article-title":"Effects of blood pressure lowering on intracranial and extracranial bleeding in patients on antithrombotic therapy. The PROGRESS trial.","volume":"43","author":"Arima","year":"2012","journal-title":"Stroke"},{"key":"R62-2-20210208","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/STROKEAHA.110.580506","article-title":"Blood pressure levels and bleeding events during antithrombotic therapy. The Bleeding with Antithrombotic Therapy (BAT) study.","volume":"41","author":"Toyoda","year":"2010","journal-title":"Stroke"},{"key":"R63-2-20210208","first-page":"409","article-title":"Arch Intern M","volume":"156","year":"1996","journal-title":"ed"},{"key":"R64-2-20210208","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1212\/WNL.53.6.1319","article-title":"for the Stroke Prevention In Reversible Ischemia Trial (SPIRIT), and European Atrial Fibrillation Trial (EAFT) Study GroupsMajor bleeding during anticoagulation after cerebral ischemia. Patterns and risk factors.","volume":"53","author":"Gorter","year":"1999","journal-title":"Neurology"},{"key":"R65-2-20210208","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0828-282X(06)70265-3","article-title":"Stroke prevention in patients with atrial fibrillation: the diagnosis and management of hypertension by specialists.","volume":"22","author":"Healey","year":"2006","journal-title":"Can J Cardiol"},{"key":"R66-2-20210208","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jacc.2011.12.014","article-title":"Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation.","volume":"59","author":"Lakkireddy","year":"2012","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HJH.0b013e3283638194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T14:58:27Z","timestamp":1746025107000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-201311000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":66,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e3283638194","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}